Oculis Holding AG Ordinary shares

Yahoo Finance • 3 days ago

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial... Full story

Yahoo Finance • 21 days ago

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet me... Full story

Yahoo Finance • 24 days ago

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DM... Full story

Yahoo Finance • 27 days ago

Citi initiates Lumentum coverage with Buy, citing AI optics leadership

[Lumentum Corporate Headquarters in San Jose, California, USA] JHVEPhoto Citi initiated coverage on Lumentum Holdings (NASDAQ:LITE [https://seekingalpha.com/symbol/LITE]) with a Buy rating, expecting more upside in the stock, beyond its c... Full story

Yahoo Finance • 28 days ago

Oculis to Participate in Upcoming September Investor Conferences

ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with s... Full story

Yahoo Finance • last month

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors

Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySeba... Full story

Yahoo Finance • last month

Oculis Holding stock price target raised to $33 from $32 at H.C. Wainwright

Investing.com - H.C. Wainwright raised its price target on Oculis Holding AG (NASDAQ:OCS) to $33.00 from $32.00 on Friday, while maintaining a Buy rating on the stock. Currently trading at $17.80, the stock sits within a broader analyst ta... Full story

Yahoo Finance • last month

Oculis Reports Q2 2025 Financial Results and Provides Company Update

ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmology. OCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with topline results exp... Full story

Yahoo Finance • last month

Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri félagsins

ZUG, Sviss, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Á öðrum ársfjórðungi 2025 vann Oculis markvisst að áframhaldandi þróun lyfja á sviði augn- og augntaugasjúkdóma. OCS-01: Innritun sjúklinga í báðar DIAMOND fasa 3 lykilrannsóknirnar er loki... Full story

Yahoo Finance • last month

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant u... Full story

Yahoo Finance • last month

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant u... Full story

Yahoo Finance • 2 months ago

Oculis upsized loan facility to access up to CHF 100 million

* Oculis Holding (NASDAQ:OCS [https://seekingalpha.com/symbol/OCS]) has amended its loan facility [https://seekingalpha.com/pr/20186034-oculis-upsized-loan-facility-to-access-up-to-chf-100-million]with funds and accounts managed by Black... Full story

Yahoo Finance • 2 months ago

Oculis Upsized Loan Facility to Access up to CHF 100 million

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases wit... Full story

Yahoo Finance • 2 months ago

Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF

ZUG, Sviss, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknifyrirtæki með áherslu á nýsköpun við meðferð á augn- og augntaugasjúkdómum í því skyni að mæta verulegu... Full story

Yahoo Finance • 2 years ago

Oculis Reports Q3 2023 Financial Results and Provides Company Update

Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery following positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular e... Full story

Yahoo Finance • 2 years ago

Oculis to Present at Upcoming November Investor Conferences

ZUG, Switzerland, and BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD,... Full story

Yahoo Finance • 2 years ago

Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema

ZUG, Switzerland and BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that t... Full story

Yahoo Finance • 2 years ago

Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

OCS-01’s positive results in Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME) were presented as a late-breaking abstract showing that the trial met primary and secondary endpoints with robust statistical significanceOn... Full story

Yahoo Finance • 2 years ago

Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema

ZUG, Switzerland, and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that... Full story

Yahoo Finance • 2 years ago

Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

Following the achievement of two positive key late-stage clinical milestones on its lead product candidate OCS-01 and recent listing on NASDAQ, Oculis is strengthening its executive leadership team with the appointment of Rebecca Weil, Ph.... Full story